Lv0
0 积分 2026-03-01 加入
The Biology and Clinical Utility of EBV Monitoring in Blood
3个月前
已完结
Epstein‐Barr virus related post‐transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation
3个月前
已完结
Efficacy of Low-Dose Rituximab as Preemptive Treatment of EBV DNA-emia After Allogeneic Hematopoietic Stem Cell Transplantation
3个月前
已完结
Risk factors for EBV reactivation and impact of graft composition following GVHD prophylaxis with rabbit ATG or PTCy
3个月前
已完结
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
3个月前
已完结
Donor activating killer cell immunoglobulin‐like receptors genes correlated with Epstein–Barr virus reactivation after haploidentical haematopoietic stem cell transplantation
3个月前
已完结
Epstein–Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes
3个月前
已完结
Rituximab for posttransplant lymphoproliferative disorder – therapeutic, preemptive, or prophylactic?
3个月前
已完结
Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT: survey of Infectious Diseases Working Party EBMT
3个月前
已完结
皖公网安备34019202002308
